CSPC PHARMA(01093.HK): Joint Venture Established with AstraZeneca, Holding 51% Stake to Co‑Build Biologics Manufacturing Base

NewTimeSpace · 2026/08/05 16:37 · By Xuran Lin

NewTimeSpace News: CSPC Pharmaceutical Group Limited (01093.HK) announced that it has signed a joint‑venture contract with AstraZeneca to set up a joint‑venture company for constructing a new‑generation biologics manufacturing base in Shijiazhuang. The Group and AstraZeneca will hold 51% and 49% equity interests respectively. The joint‑venture company will initially focus on manufacturing and supplying drug substance (DS) of biologics for the global market, and will incorporate more products into its scope of operations in future.

NewTimeSpace News: CSPC Pharmaceutical Group Limited (01093.HK) released a voluntary announcement on 5 August 2026. The Group has entered into a joint‑venture contract with AstraZeneca to establish a joint‑venture company in Shijiazhuang, Hebei Province, and build a new‑generation biologics manufacturing base.

CSPC Pharmaceutical Group will hold a 51% stake and AstraZeneca will hold 49%. Both parties will jointly manage the construction and day‑to‑day operation by leveraging their respective professional strengths. Initial business will focus on manufacturing and supplying agreed biologics drug substance (DS) for global markets. Inclusion of additional products will be explored subject to business development. The transaction is subject to customary closing conditions, including obtaining relevant regulatory approvals.

According to the Company, this cooperation represents high recognition of CSPC’s modern manufacturing system and quality‑management capabilities by a world‑leading multinational pharmaceutical enterprise. It enables the combination of CSPC’s strengths in intelligent manufacturing‑base construction and cGMP‑compliant operation with AstraZeneca’s global expertise in quality and supply‑chain management. It marks the Group’s international development journey extending from “product and technology global expansion” to “global roll‑out of manufacturing system and supply‑chain capabilities”.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

CSPC PHARMA 01093.HK AstraZeneca joint‑venture company